<DOC>
	<DOC>NCT00430729</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Main FEV1/FVC ratio (postbronchodilator) ≤70% FEV1 (postbronchodilator) ≤50% of predicted Current smoker or exsmoker Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline Availability of a chest xray dated a maximum of 6 months prior to study baseline visit B0 or a willingness to have a chest xray performed before baseline Main COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline Lower respiratory tract infection not resolved 4 weeks prior to baseline Diagnosis of asthma and/or other relevant lung disease Known alpha1antitrypsin deficiency Need for longterm oxygen therapy defined as ≥16 hours/day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
</DOC>